TOFANI, LORENZO
 Distribuzione geografica
Continente #
AS - Asia 159
NA - Nord America 153
EU - Europa 101
SA - Sud America 27
AF - Africa 6
OC - Oceania 1
Totale 447
Nazione #
US - Stati Uniti d'America 150
SG - Singapore 77
IT - Italia 39
BR - Brasile 21
CN - Cina 21
HK - Hong Kong 20
RU - Federazione Russa 18
DE - Germania 14
VN - Vietnam 14
FI - Finlandia 13
JP - Giappone 10
ID - Indonesia 5
GB - Regno Unito 4
IN - India 4
AT - Austria 3
NL - Olanda 3
PK - Pakistan 3
TN - Tunisia 3
AR - Argentina 2
CH - Svizzera 2
CO - Colombia 2
ES - Italia 2
FR - Francia 2
MA - Marocco 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BG - Bulgaria 1
CA - Canada 1
CL - Cile 1
ET - Etiopia 1
JO - Giordania 1
MX - Messico 1
MY - Malesia 1
PH - Filippine 1
PY - Paraguay 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 447
Città #
Singapore 33
San Jose 26
Council Bluffs 25
Hong Kong 19
Rome 18
Tokyo 10
Munich 8
The Dalles 8
Helsinki 6
Ashburn 5
Beijing 5
Dallas 5
Jakarta 5
New York 5
Hanoi 4
Ho Chi Minh City 4
Redondo Beach 4
Santa Clara 4
Chennai 3
Frankfurt am Main 3
Lappeenranta 3
Turin 3
Cinisello Balsamo 2
Espoo 2
Los Angeles 2
Milan 2
Moscow 2
Multan 2
Naples 2
Nuremberg 2
Qingdao 2
San Francisco 2
São Paulo 2
Turku 2
Zurich 2
Addis Ababa 1
Agadir 1
Amman 1
Bangkok 1
Baturité 1
Ben Arous 1
Bexley 1
Boardman 1
Boston 1
Brooklyn 1
Bucaramanga 1
Buffalo 1
Béja 1
Cagliari 1
Campinas 1
Can Tho 1
Caraguatatuba 1
Castlegar 1
Chaguanas 1
Champaign 1
Charleston 1
Chesapeake 1
Da Nang 1
Detroit 1
Dulles 1
Estância Velha 1
Fermignano 1
Fort Worth 1
Fortaleza 1
Foz do Iguaçu 1
Funza 1
Grenoble 1
Gualeguaychú 1
Hazard 1
Houston 1
Hyderabad 1
Ilford 1
Jackson 1
Jaguaquara 1
Johor Bahru 1
Jundiaí 1
Katueté 1
Kowloon City 1
Las Vegas 1
Lorena 1
Louisville 1
Medina 1
Mexico City 1
Muriaé 1
Nashville 1
Newark 1
North Las Vegas 1
Palmas 1
Petrópolis 1
Philadelphia 1
Phoenix 1
Phú Nhuận 1
Pisa 1
Poplar 1
Portal 1
Pudahuel 1
Punta Alta 1
Raleigh 1
Rio de Janeiro 1
Roubaix 1
Totale 297
Nome #
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 107
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 77
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 71
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice 64
Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report 53
AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks 27
Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies 23
Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study 22
Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study 22
Predictive Factors of Super-Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real-World Monocentric Study 16
Totale 482
Categoria #
all - tutte 1.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.922


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202430 0 0 0 0 0 0 22 0 0 1 0 7
2024/2025146 5 12 6 20 10 25 6 6 25 10 12 9
2025/2026306 15 11 27 8 15 3 33 28 87 74 5 0
Totale 482